Author: l.ferguson@neurotechusa.com

Home » Archives for l.ferguson@neurotechusa.com » Page 2

December 2, 2023

Rich Small, Chief Executive Officer, Presents a Company Update at the Retina Innovation Showcase at the Ophthalmology Innovation Summit (OIS) XIII

November 2, 2023

Chief Executive Officer, Rich Small Joins the Panel Discussion “Key Ingredients of Successful Innovation” at the American Academy of Ophthalmology Eyecelerator Meeting in San Francisco on November 2, 2023

October 26, 2023

Rich Small, Chief Executive Officer presents a company update at the Retina Ocular Surgery News Disruptive Innovations Symposium in New York on October 26, 2023

September 13, 2023

Alex Gorsky Appointed to Neurotech’s Board as Lead Director

June 9, 2023

Rich Small, Chief Executive Officer Joins the Executive Panel Discussion “Innovations in the Posterior Segment” at the Octane Ophthalmology Tech Forum in Newport Beach, California on June 9, 2023

July 24, 2012

NT-501 Granted Orphan-Drug Designation for Macular Telangiectasia Type 2 (MacTel)

⇧